CXCR2 and neoplasm: In addition to its inhibitory action of tumor angiogenesis through CXCR2-mediated cell signaling (Matsuo et al., 2009), our study demonstrates that SB225002 could be a potential therapeutic agents for chemoresistant OVCA through its action on cell cycle progression and apoptosis independent of receptor-mediated signaling.